Welcome to LookChem.com Sign In|Join Free
  • or
Benzamide, 4-(oxiranylmethoxy)- is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

28763-58-8

Post Buying Request

28763-58-8 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

28763-58-8 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 28763-58-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,8,7,6 and 3 respectively; the second part has 2 digits, 5 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 28763-58:
(7*2)+(6*8)+(5*7)+(4*6)+(3*3)+(2*5)+(1*8)=148
148 % 10 = 8
So 28763-58-8 is a valid CAS Registry Number.

28763-58-8SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 20, 2017

Revision Date: Aug 20, 2017

1.Identification

1.1 GHS Product identifier

Product name 4-(oxiran-2-ylmethoxy)benzamide

1.2 Other means of identification

Product number -
Other names 4-oxiranylmethoxy-benzamide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:28763-58-8 SDS

28763-58-8Relevant academic research and scientific papers

SUBSTITUTED 3-AMINO-THIENO[2,3-b]PYRIDINE-2-CARBOXYLIC ACID AMIDE COMPOUNDS AND PROCESSES FOR PREPARING AND THEIR USES

-

Page 111-112, (2008/06/13)

Disclosed are compounds of formula (I), wherein R1 and R2 are defined herein, which are useful as inhibitors of the kinase activity of the IκB kinase (IKK) complex. The compounds are therefore useful in the treatment of IKK mediated diseases including autoimmune diseases inflammatory diseases and cancer. Also disclosed are pharmaceutical compositions comprising these compounds and processes for preparing these compounds.

8-Substituted purine derivatives: a new class of lipid-lowering agents

Vanotti, E.,Bani, M.,Favara, D.,Gobetti, M.,Lombroso, M.,et al.

, p. 287 - 294 (2007/10/02)

A series of purine derivatives have been prepared and their in vivo abilities to lower plasma total cholesterol and triglyceride levels, and to elevate high density lipoprotein (HDL) cholesterol levels in hyperlipemic rats have been tested.Some compounds, among which 8-propylthio>adenosine 31, 8--2-oxopropylthio>adenosine 33 and 8--2-hydrazonecarboxamidepropylthio>adenosine 36 appear to be the most interesting, have been found to have both the desired profile of activity and no hepatotoxicity, when administered po at 50, 100 or 300 mg/kg.Compounds 31, 33 and 36, orally tested at the same doses in the 15-d test, lower triglyceride and VLDL/LDL (very low density lipoprotein / low density lipoprotein) cholesterol levels by 10-33percent and 13-46percent, respectively, and increase HDL-associated cholesterol levels by 10-32percent.These molecules have been chosen for further pharmacological and toxicological evaluations. adenosine / purine / cholesterol / triglyceride / hypolipemic agent

Substituted benzamide radiosensitizers

-

, (2008/06/13)

A method for sensitizing hypoxic tumor cells to radiation using derivatives of benzamide are disclosed. Some of the compounds useful in the REFERENCE TO GOVERNMENT GRANT OR CONTRACT The invention described herein was made in the course of work under grant or contract from the National Institutes of Health.

New 8-substituted nucleoside and purine derivatives, the process for the preparation thereof and the pharmaceutical compositions containing them

-

, (2008/06/13)

New 8-substituted nucleoside and purine derivatives of the general formula: STR1 wherein R represents an amino group or an hydroxy group possibly in the corresponding keto tautomeric form, R1 is hydrogen or an amino group, R2 is hydrogen or a β-D-ribofuranosyl radical wherein the primary hydroxy group and/or the two secondary hydroxy groups may be derivatized, R3 is an optionally substituted aryl or monocyclic heteroaryl radical and, X is --O-- or --S--. The new compounds have antihyperlipaemic activity.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 28763-58-8